Castle BiosciencesCSTL
Market Cap: $813M
About: Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Employees: 703
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
326% more call options, than puts
Call options by funds: $12.1M | Put options by funds: $2.83M
300% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 4 (+3) [Q2]
33% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 24
15% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 48
5% more funds holding
Funds holding: 150 [Q1] → 158 (+8) [Q2]
3% less capital invested
Capital invested by funds: $566M [Q1] → $548M (-$18.6M) [Q2]
1.92% less ownership
Funds ownership: 93.12% [Q1] → 91.19% (-1.92%) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Stephens & Co. Mason Carrico 68% 1-year accuracy 15 / 22 met price target | 26%upside $37 | Overweight Reiterated | 6 Aug 2024 |
Baird Catherine Ramsey 86% 1-year accuracy 6 / 7 met price target | 26%upside $37 | Outperform Maintained | 6 Aug 2024 |
Baird Catherine Ramsey 86% 1-year accuracy 6 / 7 met price target | 16%upside $34 | Outperform Maintained | 5 Jul 2024 |
Financial journalist opinion
Based on 3 articles about CSTL published over the past 30 days